ArticleBMC cancer2026
Treatment for metastatic triple-negative breast cancer with homologous recombination deficiency: a Bayesian network meta-analysis.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHomologous recombination deficiency (HRD) is a key molecular feature in a subset of triple-negative breast cancer (TNBC). The optimal treatment strategy for metastatic TNBC with HRD remains unclear despite multiple therapeutic options.
methodsA systematic search was performed in PubMed, Embase, Cochrane CENTRAL, and ClinicalTrials.gov, including conference proceedings, up to November 27, 2024. Eligible studies included randomized controlled trials and retrospective studies reporting efficacy outcomes for metastatic TNBC with HRD biomarkers. Pairwise meta-analysis using random-effects models and Bayesian network meta-analysis were conducted. Hazard ratios (HRs) or odds ratios (ORs) with 95% credible intervals (CrIs) were used. Primary outcomes included progression-free survival (PFS) and overall survival (OS); secondary outcomes were objective response rate (ORR) and adverse events (AEs). Treatment rankings were estimated using the surface under the cumulative ranking curve (SUCRA).
resultsThirteen studies with 1,341 patients and 8 treatment regimens were included. For metastatic TNBC with HRD, PARP inhibitors (PARPi), platinum-based chemotherapy (PBCT), and PARPi + PBCT significantly improved PFS compared to platinum-free chemotherapy (PFCT) (HR 0.53, 95% CrI 0.31–0.90; HR 0.60, 95% CrI 0.35–0.90; HR 0.41, 95% CrI 0.20–0.74). PARPi + PBCT ranked highest for PFS (SUCRA = 78.8%), while sacituzumab govitecan (SG) ranked highest for OS (SUCRA = 86.1%). PARPi + ATR inhibitor (ATRi) showed the highest ORR (SUCRA = 75.8%). PARPi + PBCT had the highest all-grade AEs (SUCRA = 30.5%), with PFCT having the lowest (SUCRA = 77.6%). In addition, SG was associated with the highest incidence of grade ≥ 3 AEs (SUCRA = 11.0%).
conclusionPARPi + PBCT was associated with the most favorable PFS, whereas SG ranked highest for OS in patients with metastatic TNBC with HRD. These findings highlight distinct advantages across efficacy endpoints and underscore the need to balance efficacy and safety when selecting treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.